Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		A Phase I/II Trial of PEG-Interferon Alfa-2B (PEG-Intron) for Plexiform Neurofibromas (NF1 patients)

		Phase:		Phase 1/2

		Treatment ID#:		936

		Age Group:		Adult And Pediatric

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Patients are eligible for this study if they have a progressive plexiform neurofibroma which is not surgically resectable and for which there is no standard treatment. Patients without biopsy proof of plexiform neurofibroma must have at least one other diagnostic criteria of NF1.

		Last Updated:		12/04/2005

		Tumor Types:		Pediatric Brain Tumors


		Comments:		Peg-Intron is given as a sub-Q injection once weekly. This is a dose escalaltion study starting at 3.0ug/kg/week. Each additional level will have a dose increase of 1.5 ug/kg/wk. 3-6 patients will be treated at each dose level to assess the side-effects of the treatment. The patient may be treated for up to 2 years as long as there is no tumor progression or unacceptable side-effects.

		Treatment Type:		Less-Toxics

		Contact:		Christopher Moertel MD Children`s Hospitals and Clinics - St. Paul, St. Paul, MN 55102 USA Phone: 651-220-6732 Fax: E-mail: Chris.moertel@childrenshc.org Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By